Unknown

Dataset Information

0

Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.


ABSTRACT: To evaluate the feasibility and clinical efficacy of the combination of alemtuzumab with dose-adjusted etoposide/cyclophosphamide/doxorubicin/vincristine/prednisone (DA-EPOCH) as upfront therapy for untreated aggressive T and NK cell lymphomas, a phase 1/2 trial was conducted. Thirty patients were treated with the study regimen, consisting of alemtuzumab on day 1 of a 21?day cycle with standard dosing of DA-EPOCH for 6-8 cycles. Alemtuzumab 30?mg IV was used for the phase 2 component. Of 30 treated patients, 17 had a complete response (CR) and eight had a partial response (83.3% overall response rate). The median overall survival and progression-free survival were 20.2 and 6.6 months, respectively. There were five treatment-related deaths on study mainly due to infectious complications, including one case each of disseminated toxoplasmosis and pneumonia and two cases of sepsis. Alemtuzumab with DA-EPOCH is of limited clinical utility due to unacceptable toxicity, despite the high rate of CR.

SUBMITTER: Roswarski J 

PROVIDER: S-EPMC6620167 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5709109 | biostudies-literature
| S-EPMC7831158 | biostudies-literature
| S-EPMC6342507 | biostudies-literature
| S-EPMC7392744 | biostudies-literature
| S-EPMC4568999 | biostudies-literature
| S-EPMC8814674 | biostudies-literature
| S-EPMC10241852 | biostudies-literature